Cipher Pharmaceuticals Inc. (NASDAQ:CPHR) – Investment analysts at Cormark dropped their Q3 2016 EPS estimates for shares of Cipher Pharmaceuticals in a report released on Monday. Cormark analyst D. Novak now forecasts that the brokerage will post earnings per share of ($0.10) for the quarter, down from their previous estimate of ($0.05). Cormark also issued estimates for Cipher Pharmaceuticals’ Q4 2016 earnings at ($0.06) EPS and FY2016 earnings at ($0.39) EPS.

A number of other analysts have also recently commented on the company. TD Securities reaffirmed a “buy” rating and set a $7.50 price target on shares of Cipher Pharmaceuticals in a research report on Saturday, August 13th. GMP Securities reaffirmed a “hold” rating on shares of Cipher Pharmaceuticals in a research report on Saturday, August 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Cipher Pharmaceuticals has an average rating of “Hold” and a consensus target price of $6.85.

Cipher Pharmaceuticals (NASDAQ:CPHR) opened at 3.68 on Wednesday. Cipher Pharmaceuticals has a 12-month low of $3.55 and a 12-month high of $6.37. The firm’s 50-day moving average price is $3.99 and its 200 day moving average price is $5.07. The stock’s market cap is $96.40 million.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.

5 Day Chart for NASDAQ:CPHR

Receive News & Ratings for Cipher Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.